Nutritional and clinical outcomes of chemoradiotherapy for clinical T1N0M0 esophageal carcinoma

Figures & data

Figure 1 Consort diagram.

Abbreviation: N, number of patients.

Table 1 Patient characteristics

Gender (female/male)	7/37
Median age (year) (range)	66 (55–84)
Performance status (0/1/2)	12/26/6
History of chemoradiotherapy or surgery for head and neck carcinoma or total/partial gastrectomy (with/without)	8/36
Alcohol intake
Current drinker/others	36/8
Median (range) estimated alcohol intake (g/day) in current drinkers*	48 (8–170)
Clinical T1a/T1b	22/22
Median body weight, kg (range)	55.4 (44.3–68.6)
Median body mass index, kg/m^2 (range)	20.8 (16.9–28.3)
<18.5	9
18.5–24.9	31
>25	4
Serum albumin, g/dL (range)	4.1 (3.4–4.6)
Serum C-reactive protein g/dL (range)	0.1 (0.0–1.6)

Note: *Data missing for one patient for whom there was no record of alcohol intake.

Table 2 Changes of nutritional parameters during chemoradiotherapy in 44 patients

	Pre-chemoradiotherapy	Post-chemoradiotherapy
Median body weight, kg (range)	55.4 (44.3–68.6)	52.8 (38.9–67.8)
Serum albumin, g/dL (range)	4.1 (3.4–4.6)	3.8 (2.6–4.2)
Median NRI score (range)	100.5 (89.0–113.8)	94.5 (82.2–106.8)
No risk (NRI score ≥100)	23	8
Mild risk (NRI score 97.5–100)	11	6
Moderate risk (NRI score 83.5–97.5)	10	28
Major risk (NRI score <83.5)	0	2
Serum C-reactive protein g/dL (range)	0.1 (0.0–1.6)	0.5 (0.0–27.8)

Abbreviation: NRI, nutritional risk index.

Figure 2 Cause-specific survival, overall survival, and local-regional control.

Figure 3 Overall survival of the subpopulation. (A) pre-NRI ≥100 vs pre NRI <100. (B) no decline of NRI category vs decline of NRI category during chemoradiotherapy.

Abbreviation: NRI, nutritional risk index.